EICHOR
● Active Not Recruiting
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
Condition: Multiple Sclerosis · Sponsor: Hoffmann-La Roche
About this study
This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche sponsored Parent study who continue to receive ocrelizumab or are in safety follow-up at the time of the closure of their respective Parent study (WA21092, WA21093 or WA25046) are eligible for enrollment in this extension study. Participants who will continue ocrelizumab treatment will receive IMP based on the dosage and administration received at the time of rollover from the Parent study.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (236)
| Barrow Neurological Institute | Phoenix, Arizona, United States | — |
| Arizona Neuroscience Research LLC | Phoenix, Arizona, United States | — |
| MS Center of California | Laguna Hills, California, United States | — |
| Stanford Hospital and Clinics | Palo Alto, California, United States | — |
| University of California San Francisco | San Francisco, California, United States | — |
| University of California San Francisco | San Francisco, California, United States | — |
| University of Colorado - Anschutz Medical Campus (University of Colorado Health Sciences Center) | Aurora, Colorado, United States | — |
| Advanced Neurosciences Research LLC | Fort Collins, Colorado, United States | — |
| Neurology Associates PA | Maitland, Florida, United States | — |
| University of Miami | Miami, Florida, United States | — |
| Neurological Services of Orlando | Orlando, Florida, United States | — |
| University of South Florida | Tampa, Florida, United States | — |
+ 224 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05269004